{"chunk_id": "medquad__chunk_15887", "source": "medquad", "text": "ffected systems. Asfotase alfa appears to be a valuable emerging therapy for the treatment of bone manifestations in people with pediatric-onset HPP. In October of 2015 the FDA approved asfotase alfa, sold as Strensiq. Bone marrow and stem cell transplantation in infancy and childhood have improved the severity of the disease, but have not provided long term improvement.\",GARD,Hypophosphatasia\nWhat are the symptoms of Kapur Toriello syndrome ?,\"What are the signs and symptoms of Kapur Toriello s"}